



**ESMO Advanced Course
on EGFR in Lung Cancer**

PROGRAMME

**ESMO
ADVANCED COURSE**

**HONG KONG SAR CHINA
26-27 JANUARY 2024**

Co-Chairs

Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

ESMO ADVANCED COURSE PROGRAMME

EGFR IN LUNG CANCER

Hong Kong SAR, China
26-27 January 2024

CO-CHAIRS Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

SPEAKERS Lyudmila Bazhenova, United States
Enriqueta Felip, Spain
Rina Hui, Hong Kong SAR, China
Keith M. Kerr, United Kingdom
Molly S. C. Li, Hong Kong SAR, China
David Planchard, France
Suresh S. Ramalingam, United States
Daniel S. W. Tan, Singapore
James C.-H. Yang, Taiwan
Pan-Chyr Yang, Taiwan
Thomas Y.-L. Wu, China

LEARNING OBJECTIVES

- To understand the role of molecular diagnostic test on tissue and plasma samples for diagnosis, monitoring and TKI resistance in management of epidermal growth factor receptor (EGFR) mutation positive (M+) lung cancer
- To comprehend management of early-stage and locally advanced EGFR M+ lung cancer
- To gain updated information on optimal first-line management and treatment of TKI resistance
- To interrogate the potential use of immunotherapy for patients with EGFR M+ lung cancer

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 26 January 2024

- 09:00-09:10 **Welcome and introduction**
Tony S. K. Mok, HKSAR CN
Solange Peters, CH
- 09:10-10:25 **Session 1 – Diagnosis and early detection**
(Chair: Keith M. Kerr, UK)
- 20' Biomarker testing for NSCLC: Why should it be comprehensive and/or reflex?
Keith M. Kerr, UK
- 20' The role of liquid biopsy in management of EGFR M+ lung cancer: Initial diagnosis, monitoring and resistance
Molly S. C. Li, HKSAR CN
- 20' Early detection of lung cancer among never smokers
Pan-Chyr Yang, TW
- 15' Discussion
- 10:25-10:55** **Coffee break**
- 10:55-11:50 **Session 2 – Optimal standard of care**
(Chair: Solange Peters, CH)
- 20' The art of optimal first-line therapy for patients with sensitizing or uncommon EGFR M+ lung cancer
Tony S. K. Mok, HKSAR CN
- 20' Potential combination therapy for EGFR M+ lung cancer
Rina Hui, HKSAR CN
- 15' Discussion
- 11:50-12:45 **Session 3 – EGFR TKI resistance**
(Chair: Tony S. K. Mok, HKSAR CN)
- 20' Understanding and overcoming resistance to EGFR TKI: Mechanisms and dynamics
David Planchard, FR
- 20' Treatment strategy for management of EGFR TKI resistance
Lyudmila Bazhenova, US
- 15' Discussion
- 12:45-13:45** **Lunch**
- 13:45-15:00 **Session 4 – Early EGFR M+ NSCLC**
(Chair: Daniel S. W. Tan, SG)
- 20' Adjuvant therapy for resectable EGFR M+ lung cancer
Thomas Y.-L. Wu, CN
- 20' How to manage stage III EGFR M+ lung cancer
Suresh S. Ramalingam, US
- 20' Next generation neo-adjuvant and adjuvant trials in EGFR M+ and other oncogene-addicted lung cancer (excluding IO)
Enriqueta Felip, ES
- 15' Discussion
- 15:00-15:30** **Coffee break**

15:30-16:50	Session 5 – Facing the uncertainties (Chair: Suresh S. Ramalingam, US)
25'	Role of IO in early- and advanced stage EGFR M+ lung cancer Solange Peters, CH
20'	Biology and impact of co-mutations on management of EGFR M+ lung cancer Daniel S. W. Tan, SG
20'	Novel treatment approaches to EGFR M+ lung cancer James C.-H. Yang, US
15'	Discussion and closure of the day
19:00	<i>Networking dinner</i>

Saturday, 27 January 2024

09:00-12:30	Workshop sessions
	25' Introduction based on clinical cases presented by speakers 35' Discussion
Workshop 1 60'	Oligometastasis, oligoprogression and systemic progression: How to best address Molly S. C. Li, HKSAR CN Suresh S. Ramalingam, US
Workshop 2 60'	Interrogations for early-stage EGFR M+ NSCLC Rina Hui, HKSAR CN David Planchard, FR
11:00-11:30	<i>Coffee break</i>
Workshop 3 60'	Prevention and management of brain and leptomeningeal metastases Daniel S. W. Tan, SG James C.-H. Yang, TW
12:30-12:45	Synthesis and wrap-up Tony S. K. Mok, HKSAR CN Solange Peters, CH
12:45-13:45	<i>Lunch</i>